← FDA DRUG APPROVALS

FDA ANDA · ANDA077847

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Sponsor: HIKMA

APPLICATION
ANDA077847
TYPE
ANDA
ORIGINAL APPROVAL
2008-10-28
LATEST ACTION
2025-08-22
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Discontinued

Products

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEDiscontinued
DORZOLAMIDE HYDROCHLORIDE EQ 2% BASE, TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS · OPHTHALMIC

Approval history

2025-08-22Labeling · Supplement 15 · standardAP
2021-12-03Labeling · Supplement 12 · standardAP
2020-09-04Labeling · Supplement 5 · standardAP
2011-01-28Labeling · Supplement 2AP
2009-03-06Labeling · Supplement 1AP
2008-10-28OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →